Pharmacokinetic/pharmacodynamic analysis of oral amoxicillin-clavulanic acid against extended-spectrum beta-lactamase producing Escherichia coli in an in vitro bladder infection model: impact on clinical breakpoints

Uropathogens with acquired ESBL-genes can limit effective oral treatment options. Amoxicillin with clavulanic acid can be used as targeted therapy (500/125mg, 8-hourly). Despite favorable urinary pharmacokinetics (PK), there is little urine-specific data that quantifies the exposure required for bacterial clearance. A dynamic in vitro bladder model was employed, allowing for the simulated treatment of UTIs with oral amoxicillin-clavulanic acid. Sixteen Escherichia coli isolates (12 clinical ceftriaxone-resistant uropathogens, 4 laboratory isolates) were selected. Bacterial response to treatment, emergence of resistance, exposure-response targets and PK/PD indexes were explored. Following simulation of standard-dose oral amoxicillin-clavulanic acid (500/125mg, 8-hourly; Cmax 935mg/L; AUC0-24 14272mg/L), 14/16 isolates displayed no growth at the end of treatment, with elimination in seven isolates confirmed after a 24h antibiotic-free follow up. As exposure was reduced, greater survival and regrowth were observed. Only two isolates had significant post-exposure rises in MIC (32 to 128mg/L, 64 to 256mg/L). %T>MIC was the best predictor for end of treatment outcome (?log10cfu/mL: stasis 52.7%, 1log10 kill 61.8%, 2log10 kill 71.1%, R2=0.9062). Lower R2 values were found with EUCAST MIC measurements (fixed 2mg/L clavulanic acid) as compared to CLSI MIC measurements (2:1 amoxicillin to clavulanic acid). Monte Carlo simulations indicated that standard-dose 8-hourly would achieve all %T>MIC targets in >95% of virtual patients with MICs ?64 mg/L, regardless of MIC method (CLSI or EUCAST). Amoxicillin-clavulanic acid displays time-dependent killing against ceftriaxone-resistant E. coli. This data supports clinical breakpoints for uncomplicated UTI for isolates with MIC ? 64mg/L, assuming 500/125mg oral dosing 8-hourly.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766335
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pharmacokinetic/pharmacodynamic analysis of oral amoxicillin-clavulanic acid against extended-spectrum beta-lactamase producing Escherichia coli in an in vitro bladder infection model: impact on clinical breakpoints

Cornelia B. Landersdorfer, Jason Alexander Roberts, Joseph Meletiadis, Iain J. Abbott et al.
2 links
bioRxiv (Cold Spring Harbor Laboratory)
Antibiotics Pharmacokinetics and Efficacy
preprint

Pharmacokinetic/pharmacodynamic analysis of oral amoxicillin-clavulanic acid against extended-spectrum beta-lactamase producing Escherichia coli in an in vitro bladder infection model: impact on clinical breakpoints

Cornelia B. Landersdorfer, Jason Alexander Roberts, Joseph Meletiadis, Iain J. Abbott, Connor R.B. Anderson, Elke van Gorp, Anton Yariv Peleg, Siobhonne K.J. Breen, Hugh Cottingham, Helen Won
preprint en

Abstract

Uropathogens with acquired ESBL-genes can limit effective oral treatment options. Amoxicillin with clavulanic acid can be used as targeted therapy (500/125mg, 8-hourly). Despite favorable urinary pharmacokinetics (PK), there is little urine-specific data that quantifies the exposure required for bacterial clearance. A dynamic in vitro bladder model was employed, allowing for the simulated treatment of UTIs with oral amoxicillin-clavulanic acid. Sixteen Escherichia coli isolates (12 clinical ceftriaxone-resistant uropathogens, 4 laboratory isolates) were selected. Bacterial response to treatment, emergence of resistance, exposure-response targets and PK/PD indexes were explored. Following simulation of standard-dose oral amoxicillin-clavulanic acid (500/125mg, 8-hourly; Cmax 935mg/L; AUC0-24 14272mg/L), 14/16 isolates displayed no growth at the end of treatment, with elimination in seven isolates confirmed after a 24h antibiotic-free follow up. As exposure was reduced, greater survival and regrowth were observed. Only two isolates had significant post-exposure rises in MIC (32 to 128mg/L, 64 to 256mg/L). %T>MIC was the best predictor for end of treatment outcome (?log10cfu/mL: stasis 52.7%, 1log10 kill 61.8%, 2log10 kill 71.1%, R2=0.9062). Lower R2 values were found with EUCAST MIC measurements (fixed 2mg/L clavulanic acid) as compared to CLSI MIC measurements (2:1 amoxicillin to clavulanic acid). Monte Carlo simulations indicated that standard-dose 8-hourly would achieve all %T>MIC targets in >95% of virtual patients with MICs ?64 mg/L, regardless of MIC method (CLSI or EUCAST). Amoxicillin-clavulanic acid displays time-dependent killing against ceftriaxone-resistant E. coli. This data supports clinical breakpoints for uncomplicated UTI for isolates with MIC ? 64mg/L, assuming 500/125mg oral dosing 8-hourly.

bioRxiv (Cold Spring Harbor Laboratory)
The University of Queensland (AU), National and Kapodistrian University of Athens (GR), Monash University (AU)
Australian Government, Coloplast, Shionogi, U.S. Food and Drug Administration, National Health and Medical Research Council
Good health and well-being
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon